A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs MG1 MA3 (Primary) ; Pembrolizumab
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Sandpiper Trial
  • Sponsors Turnstone Biologics
  • Most Recent Events

    • 26 Apr 2017 According to a Turnstone Biologics media release, the trial is currently recruiting patients at two sites in Canada: The Ottawa Hospital and Juravinski Cancer Centre in Hamilton, with additional study sites to be opened within the next year.
    • 26 Apr 2017 According to a Turnstone Biologics media release, treatment has been initiated on the first patient in the trial.
    • 01 Dec 2016 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top